Histopathological and Biochemical Assessment of Neuroprotective Effects of Sodium Valproate and Lutein on the Pilocarpine Albino Rat Model of Epilepsy.
Journal
Behavioural neurology
ISSN: 1875-8584
Titre abrégé: Behav Neurol
Pays: Netherlands
ID NLM: 8914585
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
01
2021
revised:
13
04
2021
accepted:
24
05
2021
entrez:
21
6
2021
pubmed:
22
6
2021
medline:
19
8
2021
Statut:
epublish
Résumé
Epilepsy is one of the most frequent neurological disorders characterized by an enduring predisposition to generate epileptic seizures. Oxidative stress is believed to directly participate in the pathways of neurodegenerations leading to epilepsy. Approximately, one-third of the epileptic patients who suffer from seizures do not receive effective medical treatment. Sodium valproate (SVP) is a commonly used antiepileptic drug (AED); however, it has toxic effects. Lutein (L), a carotenoid, has potent antioxidant and anti-inflammatory properties. The aim of this study was to determine the neuroprotective effect of sodium valproate (SVP) and lutein (L) in a rat model of pilocarpine- (PLC-) induced epilepsy. To achieve this aim, fifty rats were randomly divided into five groups. Group I: control, group II: received PLC (400 mg/kg intraperitoneally), group III: received PLC + SVP (500 mg/kg orally), group IV: received PLC + SVP + L (100 mg/kg orally), and group V: received (PLC + L). Racine Scale (RC) and latency period to onset seizure were calculated. After eight weeks, the hippocampus rotarod performance and histological investigations were performed. Oxidative stress was investigated in hippocampal homogenates. Results revealed that SVP and L, given alone or in combination, reduced the RC significantly, a significant delay in latency to PLC-kindling onset, and improved rotarod performance of rats compared with the PLC group. Moreover, L was associated with a reduction of oxidative stress in hippocampal homogenate, a significant decrease in serum tumor necrosis factor-alpha (TNF-
Identifiants
pubmed: 34149964
doi: 10.1155/2021/5549638
pmc: PMC8195670
doi:
Substances chimiques
Anticonvulsants
0
Neuroprotective Agents
0
Pilocarpine
01MI4Q9DI3
Valproic Acid
614OI1Z5WI
Lutein
X72A60C9MT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5549638Informations de copyright
Copyright © 2021 Aziza Rashed Al-Rafiah and Khlood Mohammed Mehdar.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Front Neurol. 2019 Apr 16;10:382
pubmed: 31040818
Epilepsia. 2004 Dec;45(12):1549-59
pubmed: 15571513
Nutrients. 2020 Nov 20;12(11):
pubmed: 33233594
J Epilepsy Res. 2018 Dec 31;8(2):66-73
pubmed: 30809499
Pediatr Res. 2012 Apr;71(4 Pt 2):474-81
pubmed: 22430383
Molecules. 2020 Jul 29;25(15):
pubmed: 32751250
Epilepsia. 2008 Oct;49(10):1733-48
pubmed: 18479397
Molecules. 2019 Nov 14;24(22):
pubmed: 31739417
Biochem Biophys Res Commun. 2007 Mar 30;355(1):54-60
pubmed: 17286956
Int Immunopharmacol. 2010 Dec;10(12):1560-72
pubmed: 20932499
Brain Sci. 2018 Mar 14;8(3):
pubmed: 29538301
Mol Cell Biochem. 2016 Jun;417(1-2):57-65
pubmed: 27188184
Geroscience. 2017 Feb;39(1):19-32
pubmed: 28299644
Epilepsy Curr. 2019 Sep;19(5):316-320
pubmed: 31409149
Int J Nanomedicine. 2020 Aug 24;15:6339-6353
pubmed: 32922005
Front Cell Neurosci. 2018 Nov 27;12:458
pubmed: 30542269
Neurosci Lett. 2015 Jun 15;597:49-53
pubmed: 25888816
Plant Genome. 2020 Mar;13(1):e20008
pubmed: 33016632
J Pharmacol Exp Ther. 2001 Sep;298(3):986-95
pubmed: 11504794
Neuroscience. 2011 Oct 27;194:208-19
pubmed: 21840377
Front Pharmacol. 2018 Sep 03;9:992
pubmed: 30233371
Pharmacol Res Perspect. 2017 Aug;5(4):
pubmed: 28805971
Int J Clin Exp Med. 2015 Jul 15;8(7):10508-14
pubmed: 26379841
Acta Biochim Pol. 2012;59(1):119-24
pubmed: 22428148
J Epilepsy Res. 2014 Dec 31;4(2):45-54
pubmed: 25625088
J Nutr Biochem. 2017 May;43:27-35
pubmed: 28193580
Epilepsy Behav. 2015 Jul;48:4-14
pubmed: 26037843
Prog Brain Res. 2016;226:155-78
pubmed: 27323942
Physiol Behav. 2015 May 1;143:142-50
pubmed: 25749198
Can J Physiol Pharmacol. 2017 Jun;95(6):686-696
pubmed: 28177664
Front Cell Neurosci. 2019 Mar 29;13:123
pubmed: 30983975
Cell Mol Neurobiol. 2015 Oct;35(7):1027-37
pubmed: 25971983
Biosci Biotechnol Biochem. 2018 Aug;82(8):1433-1436
pubmed: 29625535
Curr Neuropharmacol. 2014 Dec;12(6):527-50
pubmed: 25977679
Pediatr Neurol. 2017 Dec;77:23-36
pubmed: 29097018
Neurobiol Dis. 2019 Mar;123:42-58
pubmed: 29782966
Neuroscience. 2015 Aug 6;300:314-24
pubmed: 26002316
Front Cell Neurosci. 2013 Jun 18;7:89
pubmed: 23785313
Neurochem Int. 2018 Jun;116:85-94
pubmed: 29475038
Pharmacol Biochem Behav. 2001 Oct-Nov;70(2-3):291-303
pubmed: 11701200
J Tradit Complement Med. 2015 Aug 11;6(3):262-8
pubmed: 27419091
Age (Dordr). 2013 Dec;35(6):2165-76
pubmed: 23322452
J Neuroimmune Pharmacol. 2014 Mar;9(2):133-41
pubmed: 24277482
Handb Clin Neurol. 2016;138:159-71
pubmed: 27637958
Neurotoxicology. 2018 Sep;68:47-65
pubmed: 30017425
Int J Mol Sci. 2021 Feb 25;22(5):
pubmed: 33668718
Nutr Res. 2017 Dec;48:40-48
pubmed: 29246280
Pharmacol Biochem Behav. 2011 Sep;99(3):399-407
pubmed: 21641922
Neurochem Int. 2004 Mar;44(4):263-70
pubmed: 14602089
N Engl J Med. 2010 Jun 10;362(23):2185-93
pubmed: 20558369
J Adv Res. 2019 Jan 31;18:101-112
pubmed: 30847250
Mar Drugs. 2014 Jan 07;12(1):128-52
pubmed: 24402174
J Neurosci. 2007 Jul 11;27(28):7541-52
pubmed: 17626215
Anim Nutr. 2019 Dec;5(4):340-350
pubmed: 31890910
Pharmacol Rep. 2016 Dec;68(6):1301-1311
pubmed: 27693857
Heliyon. 2016 Jul 01;2(7):e00130
pubmed: 27441301
Int J Mol Sci. 2010;11(12):5109-19
pubmed: 21614195
Mar Drugs. 2018 Jul 24;16(8):
pubmed: 30042358
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2017 Jan 25;46(1):7-14
pubmed: 28436625
J Microbiol Biotechnol. 2009 Nov;19(11):1355-63
pubmed: 19996687